Solithromycin (Cempra Pharmaceuticals/Cubist Pharmaceuticals/Toyama Chemical) is a next-generation ketolide antibiotic. The drug, which is structurally related to the macrolide class of antibiotics, is the first fluoroketolide antibacterial in clinical development for bacterial infections, including CAP. In a manner similar to earlier macrolides and ketolides, solithromycin inhibits bacterial protein synthesis by binding to the bacterial ribosomes. However, the drug exhibits an enhanced mechanism of action over Ketek and macrolides, stemming from its unique ability to bind the bacterial ribosome at three different sites. This reduces the ability of bacterial strains to select resistance against it. In vitro studies indicate that solithromycin exhibited a 16-fold enhanced potency over azithromycin.
Solithromycin (Cempra Pharmaceuticals/Cubist Pharmaceuticals/Toyama Chemical) is the first fluoroketolide in clinical development for community-acquired pneumonia (CAP). In Phase III development, oral solithromycin demonstrated non-inferiority to moxifloxacin in the treatment of adult CAP patients. Cempra is currently conducting Phase III development of an intravenous (IV) form of the drug. Solithromycin’s enhanced mechanism of action enables it to demonstrate high potency against a range of bacterial pathogens, as well as retain its efficacy against bacterial strains resistant to earlier generations of macrolides. Solithromycin has also gained a regulatory advantage through a Qualified Infectious Disease Product (QIDP) designation from the US Food and Drug Administration (FDA). Datamonitor Healthcare believes that in order to benefit from these advantages, solithromycin will need to overcome negative safety perceptions associated with the use of the first ketolide antibiotic in the CAP market: Ketek (telithromycin; Sanofi). Cempra will also benefit from forging collaborations with larger pharmaceutical companies with proven experience in the antibacterials market. These would enhance the drug’s penetration in the CAP market, and maximize its commercial potential.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 solithromycin : Community-acquired pneumonia
LIST OF FIGURES
5 Figure 1: Solithromycin – development overview
9 Figure 2: Phase II data for oral solithromycin in community-acquired pneumonia
11 Figure 3: Solithromycin for community-acquired pneumonia – SWOT analysis
12 Figure 4: Datamonitor Healthcare’s drug assessment summary of solithromycin in community-
13 Figure 5: Datamonitor Healthcare’s drug assessment summary for solithromycin in
LIST OF TABLES
4 Table 1: Solithromycin drug profile
7 Table 2: Clinical development of solithromycin in community-acquired pneumonia
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.